Dr Stefanacci is a US-based Internal Medicine physician and fellowship trained Geriatrician who is an active physician caring for people with Alzheimer’s daily.
Strengthening the TauRx team as it prepares to move its lead Alzheimer’s treatment through regulatory processes, Dr Stefanacci covers three areas under the acronym “GPS”:
- GOVERNMENT: Having served as a Centers for Medicare and Medicaid (CMS) Health Policy Scholar, Dr Stefanacci has assisted with the roll out of Medicare Part D, the insurance benefit likely to cover an oral Alzheimer’s treatment such as the investigative drug being developed by TauRx.
- POLICY: In previous roles as CMO for several managed care organisations, he has gained a deep understanding of payer decision making, benefit design, and formulary management.
- SYSTEMS: Focusing on improving population health and delivery through his position as a faculty member at Thomas Jefferson University, Jefferson College of Population Health, where he teaches, publishes, and consults with health systems in the US, Europe and Asia.
In addition to Dr Stefanacci and the ongoing work with EVERSANA™ advisory teams, TauRx has enlisted regulatory legal counsel at King & Spalding, and UK-based advisors, Niche Science & Technology, to support regulatory submissions. These appointments will supplement the TauRx team to prepare for a successful commercial launch to treat Alzheimer’s disease with the aim to transform the lives of millions globally.
Dr Stefanacci will continue serving as the Chief Medical Officer for EVERSANA, a role that he has held for over 11 years. EVERSANA is a leading independent provider of global services to the life sciences industry.
TauRx welcomes new Chief Medical Officer, Dr Richard Stefanacci
